{"product_id":"9783527335381","title":"Drug Selectivity : An Evolving Concept in Medicinal Chemistry (Methods and Principles in Medicinal Chemistry)","description":"\u003cp\u003eThe book \"Drug Selectivity - An Evolving Concept in Medicinal Chemistry\" provides a current overview and comprehensive compilation for medicinal chemists that discusses the effects of aiming for multiple targets on the entire drug development process.\n\u003cbr\u003eThe result is a broad survey of current and future strategies for drug selectivity in medicinal chemistry with theoretical but also practical aspects. Different strategies are presented and evaluated, such as various design approaches, merged multiple ligands, discovery technologies and a broad range of successful examples of unselective drugs taken from all major disease areas. With its wide-ranging view of an emerging new paradigm in drug development, this handbook is of prime importance for every medicinal and pharmaceutical chemist.\n\u003cbr\u003e PART I. INTRODUCTION\n\u003cbr\u003ePolypharmacology in Drug Discovery\n\u003cbr\u003e \n\u003cbr\u003ePART II. SELECTIVITY OF MARKTETED DRUGS\n\u003cbr\u003eKinase Inhibitors\n\u003cbr\u003eNew Indications for Marketed Drugs\n\u003cbr\u003eDiscovery Technologies of New Indications\n\u003cbr\u003e \n\u003cbr\u003ePART III. FIXED-DOSE COMBINATIONS\n\u003cbr\u003eThe Growing Market of Fixed-Dose Combinations\n\u003cbr\u003e \n\u003cbr\u003ePART IV. UNSELECTIVE DRUGS IN DRUG DISCOVERY\n\u003cbr\u003eThe Growing Importance of Individualising Drugs\n\u003cbr\u003eDrug Discovery Strategies for the Generation of Multi-Target Ligands against Neglected Tropical Diseases\n\u003cbr\u003eDesigning-In Approach\n\u003cbr\u003eThe Linker Approach (Drug-Conjugates)\n\u003cbr\u003eMerged Multiple Ligands\n\u003cbr\u003ePharmacophore Generation of Multiple Ligands\n\u003cbr\u003eCellular Assays\n\u003cbr\u003e \n\u003cbr\u003ePART V. THERAPEUTIC AREAS FOR DESIGNED MULTIPLE LIGANDS\n\u003cbr\u003e5HT Transporter-Based Multiple Ligands for Depression\n\u003cbr\u003eMultiple Ligands Targeting the Angiotensin System for Hypertension \n\u003cbr\u003ePPAR-Based Multiple Ligands for Metabolic Disease\n\u003cbr\u003eAntibiotics\n\u003cbr\u003eMultiple Ligands in Cancer Therapy\n\u003cbr\u003eMultiple Ligands in Neurodegenerative Diseases\n\u003cbr\u003e Norbert Handler holds a PhD in Medicinal Chemistry from the University of Vienna, where he worked for several years as a postdoc scientist in the field of Medicinal Chemistry. He received an Erwin-Schrödinger-Scholarship and moved to ETH Zürich where he joined Professor Schubigers Group at the Center of Radiopharmaceutical Sciences. After his return to Vienna, he managed the technology transfer office at the University of Vienna before he joined Savira pharmaceuticals, Vienna, as Head of Drug Discovery and Development. Together with Helmut Buschmann he founded RD\u0026amp;C Research, Development \u0026amp; Consulting in Vienna, where he currently is working as Managing Partner. He contributed to more than 25 scientific papers and several patent applications.\n\u003cbr\u003e \n\u003cbr\u003eHelmut Buschmann has a PhD in organic chemistry from Aachen University and extensive industrial experience in medicinal chemistry, drug discovery and development, scale-up, pharmaceutical development, CMC, patent filing and prosecution. Helmut has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical\/biotechnology sectors, both in industry and academia. During his career he worked with a broad range of different targets in different therapeutic areas from pain research to anti-infectives. He has a long publication and patent record, being an author\/co-author in more than 150 scientific publications, editor of various reference books and is a named inventor\/co-inventor in more than 250 patent applications.\n\u003cbr\u003eAs a result of his research activities more than 15 NCEs within different therapeutic areas have entered the clinical phase (e.g. Rosonabant, Cizorlitine, Dulopetine, Axamadol,). Some of them have reached clinical phase III or are marketed (e.g. Tapentadol: Nucynta® Palexia®). Currently, he is Head of Chemistry, Pharmaceutical Development and Patent A_ airs at AiCuris, Wuppertal and cofounder and co-owner of RD\u0026amp;C Research, Development \u0026amp; Consulting in Vienna.\u003c\/p\u003e","brand":"Wiley-VCH","offers":[{"title":"Default Title","offer_id":49782289727736,"sku":"00000_00000_00000_00000","price":413.12,"currency_code":"AUD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0789\/8208\/6904\/files\/9783527335381-1.jpg?v=1783779656","url":"https:\/\/kinokuniya.com.au\/products\/9783527335381","provider":"Books Kinokuniya Australia","version":"1.0","type":"link"}